Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss is a common but often unreported side effect of cancer treatments, especially for breast and prostate cancers.

A cancer patient's eyelashes grew excessively without other common side effects after taking the cancer drug erlotinib.

Patients and oncologists prioritize survival benefits, while payers focus on treatment costs.

Paclitaxel is an effective cancer drug with side effects and potential new uses beyond cancer.

Cyproterone acetate with ethynyl estradiol significantly improved acne and seborrhea in women, but was less effective for hair loss and excessive hair growth.

Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.

Intravenous arsenic is safe and effective for treating certain blood cancers.

Nurses are exposed to chemotherapy drugs, risking health issues like hair loss, so protective gear and monitoring are needed.

PPX causes much less hair loss than traditional taxanes.

ICI therapy increases the risk of gastrointestinal and endocrine issues in psoriasis patients.

Cyproterone acetate with estradiol may subjectively improve excessive hair growth in women, but it's not clinically better than other treatments.

Photodynamic therapy may not work for erythroplasia of Queyrat and could lead to invasive squamous cell carcinoma.

Epristeride's metabolism in zebrafish helps improve doping detection methods.

Blocking S100A8 can reduce chemotherapy-induced hair loss.

EGFR inhibitors can cause various skin issues during cancer treatment, and managing these is important for patient care.

Topical putrescine and spermine increased DNA synthesis in hairless mouse skin.

Aminopterin strongly suppresses epithelial tissues and can treat certain skin conditions but has significant side effects.

Chemotherapy can cause various skin problems, and recognizing them helps improve patient care.

Estradiol stops hair growth in mice, but an antagonist can reverse this effect.

Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.

17b-Estradiol in skin affects hair growth and tumor promotion.

Erlotinib may cause scarring hair loss.

FOLFOX6 chemotherapy effectively reduces VEGF levels and improves quality of life in advanced colorectal cancer patients.

A woman had a delayed allergic reaction to the blood thinner enoxaparin, treated with a steroid cream.

PRIDE syndrome includes skin and hair issues from cancer treatment with EGFR inhibitors.

Curcuma aeruginosa rhizome extracts show potential as anticancer agents, with varying effectiveness against breast cancer cells.

Combining Ficlatuzumab and Gefitinib can cause severe hair loss.

Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.